secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2021-11-01T23:59:59+00:00
Accession:  0001104659-21-132367
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion appoints Seth H.Z. Fischer to its Board of Directors, effective Oct 28, 2021
--------------------------------------------------------------------------------

- Seth H.Z. Fischer elected as Class III director for term expiring at 2022 annual meeting.
- Fischer brings 35+ years pharma/device experience; former CEO of Vivus, group chairman at Johnson & Johnson.
- Will serve as chair of Nominating and Governance Committee and member of Compliance Committee.
- Board determined Fischer is an independent director under SEC and Nasdaq rules.
- Fischer receives standard non-employee director compensation; indemnification agreement executed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000110465921132367/0001104659-21-132367-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000110465921132367/tm2130916d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-132367

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer